N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses

This invention relates to antibodies, including specified portions or variants, specific for at least the human Amyloid-beta 11 N-terminal site, i.e. A 11-x peptides. It further provides methods of making and using said antibodies, including therapeutic formulations, administration and devices.

Saved in:
Bibliographic Details
Main Authors MERCKEN MARC HUBERT, VANDERMEEREN MARC MARIA PIERRE
Format Patent
LanguageChinese
English
Published 12.06.2013
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
TESTING
VINEGAR
WINE
Online AccessGet full text

Cover

Abstract This invention relates to antibodies, including specified portions or variants, specific for at least the human Amyloid-beta 11 N-terminal site, i.e. A 11-x peptides. It further provides methods of making and using said antibodies, including therapeutic formulations, administration and devices.
AbstractList This invention relates to antibodies, including specified portions or variants, specific for at least the human Amyloid-beta 11 N-terminal site, i.e. A 11-x peptides. It further provides methods of making and using said antibodies, including therapeutic formulations, administration and devices.
Author MERCKEN MARC HUBERT
VANDERMEEREN MARC MARIA PIERRE
Author_xml – fullname: MERCKEN MARC HUBERT
– fullname: VANDERMEEREN MARC MARIA PIERRE
BookMark eNqNyr8KwjAQgPEMOvjvHYKzBUOpdW5RnAqCe7kmJwaSu-JdB9_eDj6A08cHv7VZEBOuzL0rnLP6nsiDYrCQP4ljKAZUsJmJfWKCZIE0DhwiysF6ziNL1Mg0X0Z9cZBZBDsJytYsn5AEd79uzP56ebS3AkfuUUbwSKh927mjK0_1ua6apvwLfQE3Rzmj
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
Physics
ExternalDocumentID CN101367875BB
GroupedDBID EVB
ID FETCH-epo_espacenet_CN101367875BB3
IEDL.DBID EVB
IngestDate Fri Jul 19 16:00:16 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Chinese
English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_CN101367875BB3
Notes Application Number: CN200810133343
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20130612&DB=EPODOC&CC=CN&NR=101367875B
ParticipantIDs epo_espacenet_CN101367875BB
PublicationCentury 2000
PublicationDate 20130612
PublicationDateYYYYMMDD 2013-06-12
PublicationDate_xml – month: 06
  year: 2013
  text: 20130612
  day: 12
PublicationDecade 2010
PublicationYear 2013
RelatedCompanies JANSSEN PHARMACEUTICA NV
RelatedCompanies_xml – name: JANSSEN PHARMACEUTICA NV
Score 3.0063074
Snippet This invention relates to antibodies, including specified portions or variants, specific for at least the human Amyloid-beta 11 N-terminal site, i.e. A 11-x...
SourceID epo
SourceType Open Access Repository
SubjectTerms BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
TESTING
VINEGAR
WINE
Title N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20130612&DB=EPODOC&locale=&CC=CN&NR=101367875B
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fT8IwEL4g_nxT1KioaYzZE4sbdOAeiMk6CDFxoEHDG-naLswoI27ExL_eawHxidd2adpLr3df9_U7gFvqSd_zBSJVhyNA4a5Cl2r5tofBhEvBHZcbtc-o2XuljyNvVIL31VsYoxP6bcQR0aME-nthzuvZ-hIrNNzK_C5OsSl76A7bobVEx3ggY8S2wqDdGfTDPrMYa7PIil4w19XaZJicB1uwrdNorbPfeQv0q5TZ_5DSPYSdAY42LY6g9DOpwD5bVV6rwN7T8od3BXYNQ1Pk2Lj0wvwYniPbdUnxNdeCrkoS_omoO5V2jFMmuK0y8aHza4JGS-NM0wRrRFPHV_ysGlnUjc7xC0nmucpP4KbbGbKejbMc_5lkzKL1goLGKZSn2VSdAeEiTmTSQtypHEr95F41fSF8SUWiGlS2zqG6YaCLjb1VOKgvakHYbv0SyrhMdYURuYivjSl_AaqvkGU
link.rule.ids 230,309,786,891,25594,76904
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fT8IwEL4g_sA3RY2KPxpj9sQig425B2KyDoIKAw0a3kjXdhGjjLgRE_96rwXEJ17bpWkvvd593dfvAK5tR3iOxxGpVhgCFGZJdCnXMx0MJkxwVrGYVvsM6-0X-2HoDHPwvnwLo3VCv7U4InoUR3_P9Hk9XV1iBZpbmd5EY2xK7lqDRmAs0DEeyBixjcBvNPu9oEcNShs0NMJnzHWVNhkm5_4GbLoICZXOfvPVV69Spv9DSmsPtvo42iTbh9zPWxEKdFl5rQg73cUP7yJsa4YmT7Fx4YXpATyFpmWR7GumBF2lIOwTUfdYmBFOmeC2SviHyq8JGm0cJYomWCaKOr7kZ5XJvG50il8IMktleghXreaAtk2c5ejPJCMarhbk144gP0km8hgI41EsYhdxp6zYthffyrrHuSdsHsuaLdwTKK0Z6HRt7yUU2oNuZ9S5Dx9LsFud14UwreoZ5HHJ8hyjcxZdaLP-ApIak1A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=N-11+truncated+amyloid-beta+monoclonal+antibodies%2C+compositions%2C+methods+and+uses&rft.inventor=MERCKEN+MARC+HUBERT&rft.inventor=VANDERMEEREN+MARC+MARIA+PIERRE&rft.date=2013-06-12&rft.externalDBID=B&rft.externalDocID=CN101367875BB